Verve Therapeutics is a biotechnology company that is developing gene editing therapies for cardiovascular disease. The company's therapies are designed to edit genes associated with cardiovascular disease, with the goal of reducing the risk of heart attack and stroke. Verve Therapeutics was founded in 2019 by a group of scientists from the Broad Institute of MIT and Harvard, and has raised over $100 million in funding to date. The company is headquartered in Cambridge, Massachusetts.
Highest paying job titles at Verve Therapeutics include Senior Scientist, Clinical Research Scientist, and Director, IT